ArticleCureus2024
Denosumab-Induced Recurrent Severe Hypocalcaemia in a Patient With Chronic Kidney Disease: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Denosumab is a human monoclonal immunoglobulin G2 (IgG2) antibody that is used in the management of osteoporosis and various bone-related disorders to help strengthen bones and prevent fractures. Declining renal function and the drug denosumab are both associated with an increased risk of hypocalcaemia. The combination of both factors in a patient, along with the long half-life of the drug, can cause further exacerbation of this risk. A thorough understanding of pharmacokinetics is therefore essential when encountering drug adverse effects. We present a case of recurrent severe hypocalcaemia secondary to denosumab administration in a patient with chronic kidney disease. This case report highlights the importance of close monitoring of calcium levels in patients with established risk factors for hypocalcaemia, as well as in those who have achieved resolution of denosumab-induced hypocalcaemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.